Will lower-cost Humira options soon be available to patients?
“PBMs and health plans both like to do business with the branded drug companies,” said Marianne Fazen, executive director of the DFW Business Group on Health, a coalition of about 55 mid to large DFW firms. “And the reason they like it so much is because they get huge rebates and a huge spread in the cost of what the health plans and PBMs are able to share with the employers.”
Humira is a biologic drug, meaning it goes through a more complex manufacturing process than most drugs. Due to this complexity, competing companies can’t make exact replicas. Instead, they make highly similar versions, called biosimilars.These biosimilars are still expensive, but cheaper than Humira. Exact prices and drugmaker rebate incentives for biosimilars and insurers are not yet clear.
“I unfortunately think that payers and PBMs are still going to complicate the marketplace,” said Hannah Fish, strategic communications director at the National Community Pharmacists Association. “You can already see with the one biosimilar that was released earlier in January and a couple indications for those that are coming out sooner this upcoming month … the games, if you will, that are already being played as far as what the discounts are going to be projected at.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Fourth of July 2023: Where to attend July 4 parades in N.J.Check out this list of Fourth of July parades planned throughout New Jersey in 2023.
Read more »
July 4th 2023: Where to see Fourth of July parades in N.J. (June 30, 2023)Check out this list of Fourth of July parades planned throughout New Jersey in 2023.
Read more »
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Read more »
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Read more »
For AbbVie’s blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts sayLower-price biosimilar competition for top-selling drug launching this weekend.
Read more »